View Older Stories View More Recent Stories
-
Insmed (INSM) PT Lowered to $195 at Leerink Partners
-
Insmed (INSM) PT Lowered to $167 at Wolfe Research
-
Insmed discontinues nasal polyps drug program after trial fails
-
Insmed (INSM) halted, news pending
-
Insmed (INSM) PT Raised to $230 at Cantor Fitzgerald Brenso Potential
-
Western Digital stock rises after inclusion in Nasdaq-100 Index
-
Goldman Sachs Reiterates Buy Rating on Insmed (INSM)
-
'Insmed's (INSM) Quad Shot At Significant Upside'; PT Raised to $269 at TD Cowen
-
Rothschild Redburn Starts Insmed (INSM) at Buy
-
Insmed (INSM) PT Raised to $256 at Mizuho
-
European Commission approves Insmed's BRINSUPRI for bronchiectasis
-
Insmed (INSM) PT Raised to $227 at Leerink Partners
-
Insmed (INSM) PT Raised to $223 at UBS
-
Insmed (INSM) PT Raised to $223 at TD Cowen
-
Insmed (INSM) Misses Q3 EPS by 41c, provide guidance
-
Cantor Fitzgerald Assumes Insmed (INSM) at Overweight
-
UBS Reiterates Buy Rating on Insmed (INSM)
-
European regulators recommend Insmed's BRINSUPRI for rare lung disease
-
Insmed (INSM) PT Raised to $194 at UBS
-
Insmed (INSM) PT Raised to $193 at TD Cowen
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
-
Insmed (INSM) PT Raised to $172 at Guggenheim, 'continue to see it as a Top Pick'
-
Cadence Design Systems (CDNS) Goldman Updates September Directors Cut Conviction List for US
-
Insmed (INSM) PT Raised to $144 at Morgan Stanley
-
William Blair Starts Insmed (INSM) at Outperform
-
Insmed (INSM) PT Raised to $139 at Truist; 'We Remain Buyers'
-
Insmed (INSM) PT Raised to $240 at H.C. Wainwright
-
Insmed (INSM) PT Raised to $173 at Wolfe Research
-
Insmed (INSM) PT Raised to $145 at Stifel
-
Insmed (INSM) PT Raised to $154 at TD Cowen Following Brinsupri Approval
-
RBC Capital on Insmed's (INSM) Brinsupri Approval: 'Stock PT To $138.00, Buyers Into The Launch'
-
Insmed (INSM) PT Raised to $165 at Mizuho
-
Insmed (INSM) PT Raised to $140 at Wells Fargo
-
Insmed (INSM) PT Raised to $140 at UBS
-
Morgan Stanley Downgrades Insmed (INSM) to Equalweight
-
Insmed (INSM) PT Raised to $148 at Jefferies
-
FDA approves BRINSUPRI as first treatment for non-cystic fibrosis bronchiectasis
-
Insmed (INSM) Halted, News Pending
-
Insmed (INSM) PT Raised to $120 at RBC Capital
-
Insmed (INSM) PT Raised to $129 at Jefferies
-
Insmed (INSM) Misses Q2 EPS by 40c
-
Mizuho Reiterates Outperform Rating on Insmed (INSM), maintains as 'top June 2025 pick'
-
Insmed (INSM) Announces Pricing of $750 Million Public Offering of Common Stock
-
Insmed (INSM) Announces Proposed $650M Share Offering
-
Insmed (INSM) PT Raised as RBC Capital Sees 'Continued Upside From Here'
-
Insmed (INSM) PT Raised to $120 at H.C. Wainwright
-
Insmed (INSM) PT Raised to $110 at Mizuho
-
Insmed (INSM) PT Raised to $109 at BofA Securities
-
Insmed (INSM) PT Raised to $110 at Evercore ISI

